International Journal of Health & Allied Sciences

COMMENTARY
Year
: 2016  |  Volume : 5  |  Issue : 4  |  Page : 291--292

Comments on: Rare occurrence of bortezomib-induced Sweet's syndrome in multiple myeloma


Anubhav Chauhan, Lalit Gupta 
 Department of Ophthalmology, Dr. Yashwant Singh Parmar Govt. Medical College, Sirmaur, Himachal Pradesh, India

Correspondence Address:
Dr. Anubhav Chauhan
Pine Castle, Near Mist Chamber, Khalini, Shimla - 171 002, Himachal Pradesh
India




How to cite this article:
Chauhan A, Gupta L. Comments on: Rare occurrence of bortezomib-induced Sweet's syndrome in multiple myeloma.Int J Health Allied Sci 2016;5:291-292


How to cite this URL:
Chauhan A, Gupta L. Comments on: Rare occurrence of bortezomib-induced Sweet's syndrome in multiple myeloma. Int J Health Allied Sci [serial online] 2016 [cited 2023 Jun 6 ];5:291-292
Available from: https://www.ijhas.in/text.asp?2016/5/4/291/194138


Full Text

Sir,

We read with great interest the excellent article by Agrawal et al. entitled, "Rare occurrence of bortezomib-induced Sweet's syndrome in multiple myeloma."[1] We applaud the authors for diagnosing and managing the rare entity but would like to add interesting information which has not been presented.

It may also be associated with a viral upper respiratory tract infection, autoimmune diseases, inflammatory bowel diseases, and pregnancy.[2] Incidence is usually in the fourth or fifth decade with a peak in January and February. Sweet's syndrome accounts for 4/1000 new cases in a dermatological unit. It is five times more common in females than males.[3]

Involvement of the eyes, joints, oral mucosa, lungs, liver, kidneys, and central nervous system has been described.[4] Ocular involvement most commonly is in the form of conjunctivitis, others being periorbital and orbital inflammation, dacryoadenitis, episcleritis, scleritis, limbal nodules, peripheral ulcerative keratitis, iritis, glaucoma, and choroiditis. The ocular inflammation appears concurrently with skin lesions.[5]

Second, the diagnostic criteria for Sweet's syndrome have not been clearly stated by the respected authors. Diagnostic criteria for classical Sweet's syndrome versus drug-induced Sweet's syndrome are shown in [Table 1]. [6]{Table 1}

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Agrawal C, Kapoor R, Saini R. Rare occurrence of bortezomib-induced Sweet's syndrome in multiple myeloma. Int J Health Allied Sci 2016;5:178-81.
2Requena L, Kutzner H, Palmedo G, Pascual M, Fernández-Herrera J, Fraga J, et al. Histiocytoid Sweet syndrome: A dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol 2005;141:834-42.
3Lear JT, Atherton MT, Byrne JP. Neutrophilic dermatoses: Pyoderma gangrenosum and Sweet's syndrome. Postgrad Med J 1997;73:65-8.
4Von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 1994;31:535-56.
5Gottlieb CC, Mishra A, Belliveau D, Green P, Heathcote JG. Ocular involvement in acute febrile neutrophilic dermatosis (Sweet syndrome): New cases and review of the literature. Surv Ophthalmol 2008;53:219-26.
6Cohen PR. Sweet's syndrome - A comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007;2:34.